<p>BioNexus Gene Lab Corp. 已完成对 Fidelion Diagnostics Pte. Ltd. 的战略股权投资，通过非现金股权交换获得 15% 的少数股权。作为回报，Fidelion 现在持有 BioNexus Gene Lab Corp. 发行和流通股票的约 16.6%，使双方的利益保持一致。根据协议，BioNexus Gene Lab Corp. 还通过许可协议获得了 VitaGuard™ 肿瘤初始微小残留病（MRD）液体活检平台在东南亚的独家商业权利，许可费用将在 24 个月内分期支付。该交易旨在保持财务实力，最小化稀释，并支持 BioNexus Gene Lab Corp. 在精准肿瘤学市场的扩展。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。BioNexus Gene Lab Corp. 于 2025 年 12 月 03 日通过 GlobeNewswire（参考 ID：GNW9596053-en）发布了用于生成本新闻简报的原始内容，并对其中包含的信息承担全部责任。© 版权 2025 - 公共技术公司（PUBT）</p>

BGLC

<p>BioNexus Gene Lab Corp.通过非现金股权交换收购了 Fidelion Diagnostics 的 15% 股份，而 Fidelion 持有 BioNexus 16.6% 的股份。BioNexus 获得了 VitaGuard™ MRD 平台在东南亚的独家权利，以支持其在精准肿瘤学领域的扩展。该交易旨在保持财务实力并最小化稀释</p>

<p>BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.’s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.’s expansion in the precision oncology market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596053-en) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>
<div class="lb-trans"><p>BioNexus Gene Lab Corp. 已完成对 Fidelion Diagnostics Pte. Ltd. 的战略股权投资，通过非现金股权交换获得 15% 的少数股权。作为回报，Fidelion 现在持有 BioNexus Gene Lab Corp. 发行和流通股票的约 16.6%，使双方的利益保持一致。根据协议，BioNexus Gene Lab Corp. 还通过许可协议获得了 VitaGuard™ 肿瘤初始微小残留病（MRD）液体活检平台在东南亚的独家商业权利，许可费用将在 24 个月内分期支付。该交易旨在保持财务实力，最小化稀释，并支持 BioNexus Gene Lab Corp. 在精准肿瘤学市场的扩展。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。BioNexus Gene Lab Corp. 于 2025 年 12 月 03 日通过 GlobeNewswire（参考 ID：GNW9596053-en）发布了用于生成本新闻简报的原始内容，并对其中包含的信息承担全部责任。© 版权 2025 - 公共技术公司（PUBT）</p>
</div>

BioNexus Gene Lab Corp. 收购了 Fidelion Diagnostics 15% 的股份